Search
Polistes exclamans venom protein
go.drugbank.com/drugs/DB11028ApprovedPolistes exclamans venom protein is an extract of Polistes exclamans venom. Polistes exclamans venom protein is used in allergenic testing.
Vespula pensylvanica venom protein
go.drugbank.com/drugs/DB11031ApprovedVespula pensylvanica venom protein is an extract of Vespula pensylvanica venom. Vespula pensylvanica venom protein is used in allergenic testing.
Vespula vulgaris venom protein
go.drugbank.com/drugs/DB11033ApprovedVespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.
Schinus terebinthifolia pollen
go.drugbank.com/drugs/DB21762ApprovedSchinus terebinthifolia pollen is the pollen of the Schinus terebinthifolia plant. Schinus terebinthifolia pollen is mainly used in allergenic testing.
AI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Terevalefim
go.drugbank.com/drugs/DB16397InvestigationalTerevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Efletirizine
go.drugbank.com/drugs/DB20496ExperimentalThe usage of the INN stem '-rizine' in the name indicates that Efletirizine is a antihistaminic/cerebral (or peripheral) vasodilator. Efletirizine has a monoisotopic molecular weight of 390.18 Da.
Benderizine
go.drugbank.com/drugs/DB20870ExperimentalThe usage of the INN stem '-rizine' in the name indicates that Benderizine is a antihistaminic/cerebral (or peripheral) vasodilator. Benderizine has a monoisotopic molecular weight of 430.26 Da.
Aluminum acetate
go.drugbank.com/drugs/DB14518ApprovedInvestigationalProducts: ACETATO DE ALUMINIO 15 MG/100 ML SOLUCION TOPICAUbamatamab
go.drugbank.com/drugs/DB18875InvestigationalUbamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent